March 24, 2021 4pm CET / 11am EST
What will this webinar address?
R&D is the lifeblood of Pharma, and the past year has really showcased the tireless work of pharma companies, start-ups and research institutions who have developed treatments, diagnostics and vaccines against COVID-19.
Even in pre-pandemic times, the spiraling costs of drug development (estimated at an average ofUSD 2.6 billion*) mean that pharma companies have always had to think strategically about their R&D activities –staying competitive by reducing risk, managing costs and increasing time to market to justify their significant investments.
As treatments become ever more complex, how is the R&D model evolving? Should Pharma companies shift from internal R&D to relying more heavily on CROs and other partners to increase the probability of success? What new tools and technologies can the market call upon to reduce risk?
This webinar will discuss the evolution of R&D models, the outsourcing landscape, how to de-risk your development and maximise ROI.
- Internal R&D Vs Outsourcing Vs M&A
- Evolving Outsourcing Landscape in Pharma R&D
- Strategic advantages to outsourcing your R&D needs (Pros & Cons)
- What factors to consider when selecting an outsourcing partner
- How much innovation do we see coming from start-ups?
- How has COVID-19 drug development diverted R&D budgets from other therapeutic areas?
- The R&D landscape –how can the model be more sustainable?
- Digital approaches to increasing drug development success
Adrian is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian led multiple consultancy, licensing and M&A mandates. Notable deals include licensing transactions between MedGenesis and Pfizer, Esteve and Mundipharma, and M&A for a UK diagnostics business with Bruker and the sale of NanoSight to Spectris plc.
During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. He has held senior positions with Johnson & Johnson, drug discovery platform company Acumen Bioscience and the Healthcare Consultancy company Execute Technologies. Adrian has over 30 years in the pharmaceutical, biotechnology and in vitro diagnostics sectors.
Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.
VP of Business Development
Bart DeCorteserves as VP ofBusiness Development for Symeres, a chemistry and drug discovery CRO based in the Netherlands. He is also the founder of Kodib, LLC, a consultancy firm that provides drug discovery and early development expertise for pharmaceutical and biotech organizations.
Bartjoined Janssen/Johnson & Johnsonin 1993. Over the course his 20+ yearcareerat J&J, he worked inthe areas of HIV, mycology, oncology, pain, inflammation and metabolic disease.Bartis a co-inventorof INTELENCE®, J&J’sfirst FDA-approved non-nucleoside reversetranscriptase inhibitor for the treatment of HIV.
Bartcompleted his undergraduate education in Bioengineering at the University of Gent, Belgium, followed by graduate and postdoctoral work in organic chemistry at the Université de Rennes, France, the University at Albany, NY, and Vanderbilt University in Nashville, TN.
Bart is the co-author of29 peer-reviewed research papersandis aninventor onmore than 30 patents and patent applications.
Rachel Moss is a Partner in McKinsey’s Pharmaceuticals and MedTech Practice based out of London. She focuses on helping global R&D clients in this space define their R&D strategic ambitions, redesign their organisations and transform their operating models for performance. She also co-leads McKinsey’s global sub-practice on R&D operating model improvement and on merger management.